The Neurosciences Medicine (NSM) research program at the DCRI is dedicated to taking bold action to find solutions to challenging neurological conditions like depression, Alzheimer's disease, and epilepsy.

Boldly Answering Today's Neuroscience Challenges

Stock image of neuronsDriven by psychiatry and neurology faculty, the DCRI's Neurosciences Medicine program develops, conducts, and supports innovative Phase I–IV clinical trials addressing neurological and psychiatric conditions for pediatric, adolescent, adult, and geriatric patient populations.

Our experienced and consistent clinical operations teams expertly manage all aspects of neurosciences medicine clinical trials, including:

  • Early-phase PK/PD and POC trials, conducted in our onsite phase I unit
  • Game and device/sham-controlled trial design and conduct
  • Pediatrics (microdosing, PK)
  • Neurocritical care trials
  • Electroencephalography
  • Polysomnography
  • Nerve conduction studies and electromyography
  • Neuroimaging
  • Immune monitoring: mechanistic and predictive biomarkers
  • Translational studies
  • Large multisite trials
  • Full-service CRO activities (protocol design/development, data management, biostatistics, pharmacokinetics, site management/monitoring)

Our Clinical Expertise

  • Attention Deficit Hyperactivity Disorder (ADHD)
  • Autism Spectrum Disorder
  • Mood and anxiety disorders
  • Epilepsy
  • Sleep disorders
  • Neuromuscular disorders
  • Stroke
  • Neurodegenerative diseases


Christoph Hornik


About 5 percent of children are diagnosed with migraine by age 10, and a DCRI-led registry could open the door for drug development in this space.

Kathleen Welsh-Bohmer


Could the onset of Alzheimer's disease be delayed or prevented in people at high risk of developing it? Kathleen Welsh-Bohmer, PhD, was involved in the TOMMORROW trial, an innovative study that sought to find out.



Patients who experience a stroke sometimes must transfer hospitals before receiving a life-saving therapy. A DCRI study found this transfer process is associated with an increased risk of negative outcomes.

Studying a Digital Treatment for ADHD

Scott Kollins, PhD, Duke adjunct faculty and former DCRI member, shares an update on his research in ADHD and discusses DCRI’s interest in working on trials to provide clinical evidence for digital therapeutics. Read more about his research, which he conducted in collaboration with Daniel Laskowitz, MD, MHS, director for DCRI Neurosciences Medicine research:

Neurosciences Medicine Leadership at the DCRI

Daniel Laskowitz, MD, MHS, Director

Daniel Laskowitz

Daniel Laskowitz graduated from the Duke University School of Medicine. After completing his residency at the Hospital of the University of Pennsylvania, he returned to Duke to complete his residency in cerebrovascular disease and neurocritical care.

Laskowitz's research interests include exploring new therapeutic interventions in the clinical setting of stroke, intracranial hemorrhage, and closed head injury. He is committed to translational research and has several active clinical research protocols designed to bring the research performed in the Multidisciplinary Research Laboratories to the clinical arena.